S521 IgG-based Elimination Diets for Patients with IBS: Results From a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Trial

Abstract

New-onset outcomes COVID-19 vs Negative controls (n51,889,175) COVID-19 vs Influenza (n5698,253) HR (95% CI) Probability COVID Probability NC P-value HR (95% CI) Probability COVID Probability Influenza P-value Sensory neuropathy 1.12 (1.09 -1.15) 1.71% 1.53% , 0.001 0.89 (0.86 -0.92) 1.69% 1.89% , 0.001 Motor neuropathy 1.22 (1.19 -1.25) 1.52% 1.25% , 0.001 0.98 (0.95 -1.01) 1.47% 1.49% 0.247Outcomes are presented as a HR, in which the numerator consists of the COVID-19 population. The cumulative incidence of the outcomes between 3 months and 1 year after the index is presented for each cohort. A P-value was calculated using a log-rank test.